Clinical trials: Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Born out of the European Union 7th Framework Programme funded project European IPF Network (eurIPFnet), the European IPF Registry (eurIPFreg) has become Europe's leading database of longitudinal data from IPF patients, including…
- Conditions
- Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Interstitial Lung Diseases, Diffuse Parenchymal Lung Diseases
- Trial name
- eurIPFreg (NCT02951416)
- Testing
- patient registry (observation and biomaterial sampling)
- Where
- 7 sites in Austria, France and 3 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Andreas Guenther
Cystic Fibrosis,
Evaluation of Bronchial Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA)
Chronic bronchial inflammation is an important clinical feature in cystic fibrosis. Approximately 10% of patients with cystic fibrosis suffer from Allergic Bronchopulmonary Aspergillosis.
- Trial name
- ABPA (NCT00906568)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Cystic Fibrosis
Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis
In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population.
- Trial name
- Taba-Muco (NCT07342920)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Quality of Lifte, Cystic Fibrosis (CF)
Characterisation of a Population of Adults Suffering From Cystic Fibrosis in a Belgian Reference Center
This research project aims to better understand the consequences of diabetes on the quality of life, respiratory function, and nutritional status of patients with cystic fibrosis followed at a Belgian reference center and to…
- Conditions
- Quality of Lifte, Cystic Fibrosis (CF), Diabetes
- Trial name
- NCT07442682
- Where
- Belgium
- Volunteers
- 162 people
- Sponsor
- Erasme University Hospital
Idiopathic Pulmonary Fibrosis
Cough Reduction in IPF With Nalbuphine ER
The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.
- Trial name
- CORAL (NCT05964335)
- Testing
- NAL ER
- Where
- 59 sites in Australia, Canada and 8 more
- Volunteers
- 165 people
- Sponsor
- Trevi Therapeutics
Cystic Fibrosis
Non-Invasive Biomarkers in Cystic Fibrosis
Background Chronic airway inflammation is present in cystic fibrosis. Non-invasive inflammometry may be useful in disease management.
- Trial name
- NCT00413140
- Where
- 4 sites in Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Idiopathic Pulmonary Fibrosis
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a…
- Trial name
- NCT05195918
- Testing
- EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, EGCG 600 mg + Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Hal Chapman
Cystic Fibrosis
Manual Chest Physiotherapy and Active Cycle of Breathing Techniques (ACBT) in Patients of Cystic Fibrosis
Cystic fibrosis is a genetic disease (autosomal recessive) which involves malfunction of the exocrine glands, leading to abnormal secretions in the body.
- Trial name
- NCT05026918
- Testing
- MCPT, ACBT
- Where
- Pakistan
- Volunteers
- 14 people
- Sponsor
- Riphah International University
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- NCT00625079
- Testing
- sildenafil
- Where
- United States
- Sponsor
- University of California, Los Angeles
Cystic Fibrosis
A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients
The purpose of this research study is to test the pharmacokinetics, safety, and tolerability of an intravenous infusion of a drug called Ganite (gallium nitrate) in patients with cystic fibrosis.
- Trial name
- NCT01093521
- Testing
- 100 mg/m2 dose, 200 mg/m2 dose
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Cystic Fibrosis
Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways
The general objective is to elucidate the mechanisms whereby sex hormones may modulate the severity of respiratory disease. An important component of this proposal is a systematic and intensive approach to characterize how the…
- Trial name
- NCT00700050
- Testing
- Hypertonic saline
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Cystic Fibrosis
Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
This study will provide important mechanistic information regarding the effect of inhaled mannitol (Bronchitol) in people with cystic fibrosis (PwCF) with moderate to severe disease who are already using…
- Trial name
- NCT05740618
- Testing
- Mannitol Inhalant Product
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of North Carolina, Chapel Hill
Interstitial Lung Disease, Interstitial Pulmonary Fibrosis
Enhancing Physical Activity in Patients With Interstitial Lung Disease
The level of physical activity (PA) has been shown to be an important predictor for morbidity and mortality in patients with chronic respiratory diseases such as COPD and more recently Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT04138173
- Testing
- Tele coaching intervention
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- KU Leuven
Cystic Fibrosis
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
This study will evaluate the safety and pharmacokinetics (PK) of lumacaftor (LUM) and ivacaftor (IVA) in participants 1 to less than 2 years of age with cystic fibrosis (CF), homozygous for F508del (F/F).
- Trial name
- NCT03601637
- Testing
- LUM, IVA
- Where
- 27 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.
An increase in the prevalence of infections due to non-tuberculous mycobacteria (NTM) is observed in many countries and recent data suggest the circulation of dominant clones with a possibility of human-to-human contamination.
- Trial name
- CIMENT (NCT03312075)
- Testing
- Sputum and blood samples
- Where
- 14 sites in France
- Volunteers
- 848 people
- Sponsor
- University Hospital, Brest
Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases
Social distancing during the COVID-19 pandemic could lead to clinical and functional deterioration of people living with chronic respiratory diseases (CRD).
- Conditions
- Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, Asthma Chronic
- Trial name
- NCT04693975
- Where
- Brazil
- Volunteers
- 94 people
- Sponsor
- Universidade Estadual de Londrina
Cystic Fibrosis
Impact of Global Care of the Pain at Chronic Painful Patients Affected by Cystic Fibrosis
The purpose of this study is to evaluate the impact of the global approach to the pain in cystic fibrosis patients with chronic or intermittent pain.
- Trial name
- MUCO-SOPHRO (NCT01915875)
- Testing
- sophrology sessions at home
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis
Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis.
- Trial name
- NCT00737100
- Testing
- Tiotropium bromide 5 mcg, tiotropium bromide-low dose-2.5mcg
- Where
- 107 sites in United States, Australia and 9 more
- Volunteers
- 510 people
- Sponsor
- Boehringer Ingelheim
Telomere Disease
Low-Dose Danazol for the Treatment of Telomere Related Diseases
Background: DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA.
- Trial name
- NCT03312400
- Testing
- Danazol
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cystic Fibrosis, Hypoestrogenism
Estrogen Supplementation and Bone Health in Women With CF
The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF).
- Trial name
- STURDY (NCT05704036)
- Testing
- Transdermal estrogen, Progesterone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University